Rifabutin treatment methods, uses, and compositions

Inventors

Dale, Glenn E. • Lociuro, Sergio • Kemmer, Christian • Trebosc, Vincent • Gitzinger, Marc

Assignees

Bioversys AG

Abstract

The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.

Core Innovation

The invention relates to treating A. baumannii infection by administering to a patient a composition comprising rifabutin. The composition is given at a dose sufficient for activation of a ferric-coprogen (FhuE) receptor of A. baumannii cells, thereby facilitating entry of rifabutin into A. baumannii cells.

The composition is administered intravenously, by inhalation, or by modified release oral drug delivery system. The described treatment further includes quantitative pharmacokinetic constraints based on Cmax and AUC.

In addition to dose sufficient for FhuE receptor activation, dependent claim coverage includes compositions and formulations that support rifabutin delivery. Liquid formulations are defined as comprising rifabutin, water, a solvent, and an acid.

Claims Coverage

The document contains two independent claims. The first covers a treatment method with rifabutin dose selection to activate the ferric-coprogen (FhuE) receptor and facilitate rifabutin entry into A. baumannii cells, including administration route options. The second independent claim covers a rifabutin liquid composition for treating A. baumannii infection including specific compositional elements for formulation.

Across the independent claims, the inventive core is selecting and delivering rifabutin in a way that activates the ferric-coprogen (FhuE) receptor of A. baumannii to facilitate rifabutin entry, together with defined administration routes and a liquid formulation comprising rifabutin, water, a solvent, and an acid.

Stated Advantages

Documented Applications